Go to the site for US Healthcare Professionals  |  Prescribing Information  |  Select Important Safety Information
Rubraca logo

RUBRACA® (RUCAPARIB) TABLETS
ARE AVAILABLE TODAY
AND WILL BE TOMORROW

Rubraca® (rucaparib) tablets are now owned by pharmaand GmbH (pharma&). pharma& recognizes the importance of starting and continuing your treatment with Rubraca. We are committed to ensuring uninterrupted product supply to healthcare professionals and their patients, and all strengths of Rubraca are and will remain available in the US. pharma& is dedicated to providing seamless access to Rubraca and to all of our products.

TALK TO YOUR DOCTOR TO SEE IF RUBRACA MAY BE RIGHT FOR YOU

Rubraca is a PARP inhibitor approved to treat and benefit patients across two tumor types.

Recurrent BRCAmut+ Ovarian Cancer Maintenance

Rubraca is for the maintenance treatment of recurrent ovarian cancer in adult patients with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene when their cancer has come back and they are in response (complete or partial response) to a platinum-based chemotherapy.

BRCAmut+ mCRPC

Rubraca is for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult patients with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene who have received androgen receptor-directed therapy and a taxane-based chemotherapy.

FOCUS ON YOUR CARE AND FIND THE SUPPORT YOU NEED

Enroll for coverage assistance
Complete the Rubraca Enrollment and Comprehensive Support Form with your doctor. From there, we will help determine which coverage options are best for you.

ENGLISH

Financial support may include:

Starting Rubraca Tablets

Rubraca is not available at your local drugstore. You can receive Rubraca from the specialty pharmacy, which can call you with more information and mail your treatment to you.
Your doctor’s office may have a pharmacy that dispenses Rubraca. If so, ask your doctor about your Rubraca delivery.

You may report adverse events to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

You may also report adverse events, product complaints, or medical information inquiries to pharma& at 1-800-506-8501.

For questions outside of adverse event reporting, product complaints, or medical information inquiries, please contact contact@pharmaand.com.

BRCA, breast cancer susceptibility gene; BRCAmut+, BRCA-mutation positive, which includes mutations in the BRCA1 and/or BRCA2 gene; PARP, poly (ADP-ribose) polymerase.

What is Rubraca used for?
Rubraca tablets are a prescription medicine used in adults for:
  • the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene for patients whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy.
  • the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
    • that has spread to other parts of the body, and
    • has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.
  • Your healthcare provider will perform a test to make sure Rubraca is right for you.
It is not known if Rubraca is safe and effective in children.
What Warnings should you know about Rubraca?
Rubraca tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca. Symptoms of low blood cell counts are common during treatment with Rubraca, but can be a sign of serious problems, including MDS or AML.
You should not use Rubraca if:
  • you are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
    • Talk to your healthcare provider about birth control methods that may be right for you
    • Tell your healthcare provider right away if you become pregnant
  • you are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.
If you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.
What other important information should I know about Rubraca?
Your healthcare provider will do blood tests before and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.
Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.
What are the side effects of Rubraca?
The most common side effects of Rubraca in people with ovarian cancer include:
nausea, tiredness or weakness, decrease in hemoglobin (anemia), changes in liver and kidney function tests, vomiting, diarrhea, decreased appetite, low blood cell counts, changes in how food tastes, shortness of breath, dizziness, indigestion, reaction to sunlight
The most common side effects of Rubraca in people with prostate cancer include:
tiredness or weakness, nausea, decrease in hemoglobin (anemia), changes in liver function tests, decreased appetite, rash, constipation, low blood cell counts, vomiting, diarrhea
What other medications might interact with Rubraca?
Rubraca can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to pharma& at 1-800-506-8501.
Please see full Prescribing Information for additional Important Safety Information.
IMPORTANT: The information on this website is based on the US prescribing information (US PI)

Use of this website is subject to our Privacy Policy and Disclaimers. © 2023 pharmaand GmbH.
PM12-08/23